Skip navigation icon

The Knowledge-Sharing Platform

17 Mar 2020

Commission offers financing to innovative vaccines company CureVac

On 16 March 2020, the Commission offered up to €80 million of financial support to CureVac, a higly innovative vaccine developer from Tübingen, Germany, to scale up development and production of a vaccine against the Coronavirus in Europe. Commission President Ursula von der Leyen and Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, discussed with the CureVac management via videoconference. The Vice-President of the European Investment Bank (EIB), Ambroise Fayolle, also participated. The support would come in form of an EU guarantee of a currently assessed EIB loan of an identical amount, in the framework of the InnovFin Infectious Disease Finance Facility under Horizon 2020.

In 2014, CureVac won EU's first ever Horizon 2020 innovation inducement prize. Now the Commission and the EIB are strengthening jointly their efforts to provide the necessary means to CureVac, taking advantage of their long and fruitful cooperation in financial instruments dedicated to support research and innovation such as Horizon 2020 InnovFin and in particular its Infectious Disease Finance Facility.

EC Press Release


Share this page: Share on Linkedin Share on Twitter Share on Google+ Share on Facebook